Avenue Therapeutics (NASDAQ:ATXI) Releases Earnings Results, Misses Expectations By $5.38 EPS

Avenue Therapeutics (NASDAQ:ATXI) issued its earnings results on Friday. The company reported ($6.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($5.38), Zacks reports.

Avenue Therapeutics Trading Up 0.6 %

NASDAQ:ATXI traded up $0.02 on Monday, hitting $2.49. The company’s stock had a trading volume of 32,123 shares, compared to its average volume of 67,814. Avenue Therapeutics has a one year low of $2.25 and a one year high of $78.75. The firm has a market capitalization of $2.34 million, a P/E ratio of -0.32 and a beta of -0.19. The stock has a fifty day moving average of $3.30 and a two-hundred day moving average of $7.06.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.